Heart Ebitda from 2010 to 2025

HSCSW Stock  USD 0.05  0.00  0.000002%   
Heart Test EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -5.8 M in 2025. During the period from 2010 to 2025, Heart Test EBITDA regression line of quarterly data had mean square error of 734.7 B and geometric mean of  4,102,964. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-5.5 M
Current Value
-5.8 M
Quarterly Volatility
1.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Heart Test financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Heart Test's main balance sheet or income statement drivers, such as Depreciation And Amortization of 58.5 K, Interest Expense of 242.9 K or Selling General Administrative of 2.5 M, as well as many indicators such as Price To Sales Ratio of 150, Dividend Yield of 0.0 or PTB Ratio of 0.49. Heart financial statements analysis is a perfect complement when working with Heart Test Valuation or Volatility modules.
  
Check out the analysis of Heart Test Correlation against competitors.

Latest Heart Test's Ebitda Growth Pattern

Below is the plot of the Ebitda of Heart Test Laboratories over the last few years. It is Heart Test's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Heart Test's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Heart Ebitda Regression Statistics

Arithmetic Mean(4,228,677)
Geometric Mean4,102,964
Coefficient Of Variation(25.66)
Mean Deviation860,587
Median(3,734,464)
Standard Deviation1,085,014
Sample Variance1.2T
Range3.9M
R-Value(0.65)
Mean Square Error734.7B
R-Squared0.42
Significance0.01
Slope(147,255)
Total Sum of Squares17.7T

Heart Ebitda History

2025-5.8 M
2024-5.5 M
2023-6.2 M
2022-6.1 M
2021-4.4 M
2020-2.3 M

About Heart Test Financial Statements

Heart Test investors use historical fundamental indicators, such as Heart Test's Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Heart Test. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-5.5 M-5.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Heart Stock Analysis

When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.